Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Ying C Ou"'
Autor:
Constantine Tam, Mazyar Shadman, Jeff Sharman, Gavin Cull, Tycel Phillips, Judith Trotman, Aileen Cohen, Heather Allewelt, Rocco Crescenzo, Richard Delarue, Heather Zhang, Bilal Tariq, Sri Sahasranaman, Ying C Ou, Ian W Flinn
Publikováno v:
HemaSphere, Vol 7, p e70124b5 (2023)
Externí odkaz:
https://doaj.org/article/8d11dcd7c056425c884e00b51e99bc6f
Autor:
Kun Wang, Xueting Yao, Miao Zhang, Dongyang Liu, Yuying Gao, Srikumar Sahasranaman, Ying C. Ou
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 5, Pp 441-454 (2021)
Abstract A physiologically based pharmacokinetic (PBPK) model was developed to evaluate and predict (1) the effect of concomitant cytochrome P450 3A (CYP3A) inhibitors or inducers on the exposures of zanubrutinib, (2) the effect of zanubrutinib on th
Externí odkaz:
https://doaj.org/article/c6ef1cbd2e704a50ba2bf248d270e404
Autor:
Ying C. Ou, Lucy Liu, Bilal Tariq, Kun Wang, Ashutosh Jindal, Zhiyu Tang, Yuying Gao, Srikumar Sahasranaman
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 2, Pp 764-772 (2021)
Zanubrutinib is a potent, second‐generation Bruton’s tyrosine kinase inhibitor that is currently being investigated in patients with B‐cell malignancies and recently received accelerated approval in the United States for treatment of relapsed/r
Externí odkaz:
https://doaj.org/article/879d1e514a2645fb9a2b15ee786ead7c
Autor:
Song Mu, Borje Darpo, Zhiyu Tang, William Novotny, Manal Tawashi, Hongqi Xue, Michael Willett, Leo Lin, Sri Sahasranaman, Ying C. Ou
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 5, Pp 923-931 (2020)
This thorough QT (TQT) study evaluated the effect of zanubrutinib on electrocardiogram (ECG) parameters by using concentration‐QTc (C‐QTc) analysis as the primary analysis for this study. Part A of the study determined the safety and tolerability
Externí odkaz:
https://doaj.org/article/e0ea160c88114e70927aa41ba7867992
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 6, Pp n/a-n/a (2021)
Abstract Zanubrutinib is a highly selective, potent, orally available, targeted covalent inhibitor (TCI) of Bruton's tyrosine kinase (BTK). This work investigated the in vitro drug metabolism and transport of zanubrutinib, and its potential for clini
Externí odkaz:
https://doaj.org/article/5b5ab68ce63d4effa6ef18a32a9a79e9
Publikováno v:
Clinical Pharmacology in Drug Development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aeb2352cfb29ba03e62919a088fe2dbc
https://doi.org/10.1002/cpdd.1250
https://doi.org/10.1002/cpdd.1250
Autor:
Bilal Tariq, Ying C. Ou, Jennifer C. Stern, Vaibhav Mundra, Nicole Wong Doo, Patricia Walker, Katharine L. Lewis, Chester Lin, William Novotny, Srikumar Sahasranaman, Stephen Opat
Publikováno v:
Leukemialymphoma.
BTK inhibitor exposure increases significantly when coadministered with CYP3A inhibitors, which may lead to dose-related toxicities. This study explored the pharmacokinetics, efficacy, and safety of zanubrutinib when coadministered with moderate or s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::530376c8d80a16d1bdc978175a307856
https://pubmed.ncbi.nlm.nih.gov/36480811
https://pubmed.ncbi.nlm.nih.gov/36480811
Publikováno v:
Expert Review of Clinical Pharmacology. 14:1329-1344
Introduction: Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-cell lymphomas. Zanubrutinib was designed to achieve improved therapeutic concentrations and minimize off-target activities putatively accounting, in part,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::280a4c62753bb5a1b99f9438b96c1299
https://doi.org/10.1080/17512433.2021.1978288
https://doi.org/10.1080/17512433.2021.1978288
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma
Autor:
Lucy Liu, Ying C. Ou, Srikumar Sahasranaman, William Novotny, Yuying Gao, Zhiyu Tang, Aileen Cohen, Kun Wang
Publikováno v:
Leukemia & Lymphoma. 62:2612-2624
This report summarizes a totality-of-evidence approach supporting recommendation of a 320-mg total daily dose, either as 160-mg twice daily (BID) or 320-mg once daily (QD) for zanubrutinib in patients with mantle cell lymphoma. Data were derived from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da9feb3631d09fe92cb07e23617a28de
https://doi.org/10.1080/10428194.2021.1929961
https://doi.org/10.1080/10428194.2021.1929961
Autor:
Yuying Gao, Ashutosh Jindal, Ying C. Ou, Kun Wang, Srikumar Sahasranaman, Zhiyu Tang, Lucy Liu, Bilal Tariq
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 2, Pp 764-772 (2021)
Clinical and Translational Science, Vol 14, Iss 2, Pp 764-772 (2021)
Zanubrutinib is a potent, second‐generation Bruton’s tyrosine kinase inhibitor that is currently being investigated in patients with B‐cell malignancies and recently received accelerated approval in the United States for treatment of relapsed/r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9f142d63718679019ba34c981aa632
https://doi.org/10.1111/cts.12948
https://doi.org/10.1111/cts.12948